Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AN2 Therapeutics Inc (ANTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ANTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 46.42% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 30.06M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 3 | Beta -0.08 | 52 Weeks Range 0.97 - 1.68 | Updated Date 08/29/2025 |
52 Weeks Range 0.97 - 1.68 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.31 | Actual -0.21 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.54% | Return on Equity (TTM) -44.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -32857219 | Price to Sales(TTM) - |
Enterprise Value -32857219 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.11 | Shares Outstanding 27326200 | Shares Floating 17736594 |
Shares Outstanding 27326200 | Shares Floating 17736594 | ||
Percent Insiders 25.39 | Percent Institutions 39.54 |
Upturn AI SWOT
AN2 Therapeutics Inc
Company Overview
History and Background
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with significant unmet needs. Founded in 2018, they went public in 2023. Their initial focus is on developing treatments for nontuberculous mycobacterial (NTM) lung disease.
Core Business Areas
- Pharmaceutical Development: AN2 focuses on research, development, and commercialization of therapies for rare infectious diseases.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company has a typical biotech organizational structure with departments focused on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Epetraborole: Epetraborole is AN2 Therapeutics' lead product candidate, an investigational, potentially once-daily oral treatment for patients with NTM lung disease. It is currently in clinical trials. The NTM lung disease market is competitive with companies such as Insmed (INSM) with Arikayce and other off-label antibiotics.
Market Dynamics
Industry Overview
The pharmaceutical industry is constantly evolving, with a strong focus on developing novel therapies, especially for infectious diseases. Market access and regulatory approvals are critical for success.
Positioning
AN2 is positioned as a company specializing in rare and serious infectious diseases, specifically targeting NTM lung disease. Their competitive advantage lies in their potentially novel oral treatment approach.
Total Addressable Market (TAM)
The global NTM lung disease market is estimated at several billion dollars. AN2 is positioned to capture a portion of this TAM if Epetraborole is successfully developed and approved.
Upturn SWOT Analysis
Strengths
- Novel drug candidate (Epetraborole)
- Focus on unmet medical need (NTM lung disease)
- Experienced management team
- Oral formulation, potentially improving patient compliance
Weaknesses
- Single product focus (Epetraborole)
- Dependence on clinical trial success
- Requires significant funding for R&D and commercialization
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results could lead to rapid market adoption
- Potential for expansion to other indications or diseases
- Strategic partnerships with larger pharmaceutical companies
- Orphan drug designation and expedited regulatory pathways
Threats
- Clinical trial failures
- Competition from existing or new therapies
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- INSM
Competitive Landscape
AN2's advantage is potentially its oral formulation, but Insmed has an established presence with an inhaled therapy. Other off-label antibiotics also compete in the market.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progression of Epetraborole through clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of Epetraborole. Analyst estimates are based on assumptions about clinical trial outcomes and market penetration.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Epetraborole and regulatory interactions with the FDA.
Summary
AN2 Therapeutics is a high-risk, high-reward development-stage biopharmaceutical company focused on NTM lung disease. Success hinges on the clinical development of Epetraborole. The company needs to successfully navigate clinical trials, regulatory hurdles, and competitive pressures. Their oral drug format holds a great deal of promise, but faces many obstacles. Positive clinical trial results are essential for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- AN2 Therapeutics SEC filings (10-K, 10-Q)
- Company Website
- Analyst reports
- Industry reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investing in pharmaceutical companies, especially development-stage companies, involves significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AN2 Therapeutics Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2022-03-25 | Co-Founder, CEO, President & Chairman of the Board Mr. Eric E. Easom | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.an2therapeutics.com |
Full time employees 22 | Website https://www.an2therapeutics.com | ||
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.